leadf
logo-loader
viewOpen Orphan PLC
(
AIM:ORPHFRA:CRO
)

Open Orphan's Cathal Friel details new £3.5mln RSV study agreement

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after signing a new deal with a US biotech for the provision of a respiratory syncytial virus human challenge study.

He says the contract is projected to deliver £3.5mln in revenue all of which is expected to be recognised in 2020.

Quick facts: Open Orphan PLC

Follow
AIM:ORPH

Price: 22.625 GBX

Market Cap: £151.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan reveal 'very good first half, firmly profitable, cash in bank...

Open Orphan PLC (AIM:ORPH, FRA:CRO)'s (LON:ORPH) Cathal Friel talks to Proactive London about their year-on-year revenue growth and profitable first half following a 'year of turnaround and transition in 2020'.  As Friel explains, these results show a continued pattern of profitability from...

5 days, 11 hours ago

2 min read